Protagonist Therapeutics

PTGX

Market cap $3.85B

Overview Fund Activity

61.84 USD

+2.62

4.42%

At close Updated Sep 18, 2:12 PM EDT

1 day

4.42%

5 days

2.38%

1 month

10.02%

3 months

14.69%

6 months

13.43%

Year to date

58.65%

1 year

38.13%

5 years

181.09%

10 years

428.55%

About: Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Employees: 130

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

55% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 77

25% more capital invested

Capital invested by funds: $3.15B [Q1] → $3.92B (+$773M) [Q2]

8.04% more ownership

Funds ownership: 106.45% [Q1] → 114.5% (+8.04%) [Q2]

2% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 49

0% more funds holding in top 10

Funds holding in top 10: 14 [Q1] → 14 (+0) [Q2]

1% less funds holding

Funds holding: 274 [Q1] → 271 (-3) [Q2]

12% less call options, than puts

Call options by funds: $18.4M | Put options by funds: $20.8M

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$69

12% upside

Avg. target

$74

19% upside

High target

$80

29% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Douglas Tsao	$80	Buy Reiterated	17 Sep 2025
Barclays Etzer Darout	$72	Overweight Initiated	17 Sep 2025
Leerink Partners Faisal Khurshid	$73	Outperform Initiated	12 Sep 2025
JMP Securities Jonathan Wolleben	$69	Market Outperform Maintained	7 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about PTGX published over the past 30 days

Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 11:30 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Douglas Tsao - H.C.

Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director Welcome to the second day of the Citi Biopharma Back to School Summit. I'm Geoff Meacham.

Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

The Motley Fool

Protagonist (PTGX) Q2 Revenue Falls 26%

Protagonist (PTGX) Q2 Revenue Falls 26%

Protagonist (PTGX) Q2 Revenue Falls 26%

Zacks Investment Research

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th Phase 3 VERIFY trial data set of rusfertide in polycythemia vera (PV) presented during plenary session at ASCO; U.S. NDA filing on track for Q4 Cash, cash equivalents and marketable securities of $673.0 million as of June 30, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / August 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. "Thus far, 2025 has been a year of breakthrough accomplishments for Protagonist, as we saw rusfertide the topic of the prestigious ASCO Plenary Session in May, the announcement of an oral and injectable triple agonist anti-obesity peptide development candidate in June, and most recently the first ever NDA filing of icotrokinra for psoriasis last month," said Dinesh V.

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Investors Business Daily

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13754335 The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86 A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case

Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & Johnson and Takeda provide significant milestone payments, royalties, and potential for $500M–$1B annual revenue by 2030, I'd speculate. A robust cash position and a promising preclinical obesity program enhance Protagonist's strategic value and acquisition appeal.

Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeti.

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

See News Rankings

Charts implemented using Lightweight Charts™